Psychedelics promote plasticity by directly binding to BDNF receptor TrkB
Psychedelics produce fast and persistent antidepressant effects and induce neuroplasticity resembling the effects of clinically approved antidepressants. We recently reported that pharmacologically diverse antidepressants, including fluoxetine and ketamine, act by binding to TrkB, the receptor for BDNF. Here we show that lysergic acid diethylamide (LSD) and psilocin directly bind to TrkB with affinities 1,000-fold higher than those for other antidepressants, and that psychedelics and antidepressants bind to distinct but partially overlapping sites within the transmembrane domain of TrkB dimers. The effects of psychedelics on neurotrophic signaling, plasticity and antidepressant-like behavior in mice depend on TrkB binding and promotion of endogenous BDNF signaling but are independent of serotonin 2A receptor (5-HT2A) activation, whereas LSD-induced head twitching is dependent on 5-HT2A and independent of TrkB binding. Our data confirm TrkB as a common primary target for antidepressants and suggest that high-affinity TrkB positive allosteric modulators lacking 5-HT2A activity may retain the antidepressant potential of psychedelics without hallucinogenic effects.
Citations by journals
1
2
3
4
5
6
7
|
|
Molecular Psychiatry
|
Molecular Psychiatry
7 publications, 8.75%
|
Neuropsychopharmacology
|
Neuropsychopharmacology
4 publications, 5%
|
Pharmacological Reports
|
Pharmacological Reports
4 publications, 5%
|
Journal of Psychiatric Practice
|
Journal of Psychiatric Practice
2 publications, 2.5%
|
Frontiers in Pharmacology
|
Frontiers in Pharmacology
2 publications, 2.5%
|
Pharmacology Biochemistry and Behavior
|
Pharmacology Biochemistry and Behavior
2 publications, 2.5%
|
European Archives of Psychiatry and Clinical Neuroscience
|
European Archives of Psychiatry and Clinical Neuroscience
2 publications, 2.5%
|
Journal of Psychopharmacology
|
Journal of Psychopharmacology
2 publications, 2.5%
|
Nature Reviews Neuroscience
|
Nature Reviews Neuroscience
1 publication, 1.25%
|
Frontiers in Molecular Neuroscience
|
Frontiers in Molecular Neuroscience
1 publication, 1.25%
|
European Neuropsychopharmacology
|
European Neuropsychopharmacology
1 publication, 1.25%
|
Pharmaceutics
|
Pharmaceutics
1 publication, 1.25%
|
Expert Opinion on Drug Safety
|
Expert Opinion on Drug Safety
1 publication, 1.25%
|
Journal of Psychoactive Drugs
|
Journal of Psychoactive Drugs
1 publication, 1.25%
|
Molecules
|
Molecules
1 publication, 1.25%
|
Comprehensive Psychoneuroendocrinology
|
Comprehensive Psychoneuroendocrinology
1 publication, 1.25%
|
ACS Pharmacology & Translational Science
|
ACS Pharmacology & Translational Science
1 publication, 1.25%
|
Philosophical Psychology
|
Philosophical Psychology
1 publication, 1.25%
|
Personalized Medicine in Psychiatry
|
Personalized Medicine in Psychiatry
1 publication, 1.25%
|
Expert Opinion on Investigational Drugs
|
Expert Opinion on Investigational Drugs
1 publication, 1.25%
|
Naunyn-Schmiedeberg's Archives of Pharmacology
|
Naunyn-Schmiedeberg's Archives of Pharmacology
1 publication, 1.25%
|
Neuroscientist
|
Neuroscientist
1 publication, 1.25%
|
Nature
|
Nature
1 publication, 1.25%
|
Drug Discovery Today
|
Drug Discovery Today
1 publication, 1.25%
|
Pharmaceuticals
|
Pharmaceuticals
1 publication, 1.25%
|
Journal of Neuroscience
|
Journal of Neuroscience
1 publication, 1.25%
|
Annales Pharmaceutiques Francaises
|
Annales Pharmaceutiques Francaises
1 publication, 1.25%
|
Nature Reviews Drug Discovery
|
Nature Reviews Drug Discovery
1 publication, 1.25%
|
Biology
|
Biology
1 publication, 1.25%
|
1
2
3
4
5
6
7
|
Citations by publishers
5
10
15
20
25
|
|
Springer Nature
|
Springer Nature
25 publications, 31.25%
|
Elsevier
|
Elsevier
14 publications, 17.5%
|
Multidisciplinary Digital Publishing Institute (MDPI)
|
Multidisciplinary Digital Publishing Institute (MDPI)
7 publications, 8.75%
|
Frontiers Media S.A.
|
Frontiers Media S.A.
4 publications, 5%
|
Taylor & Francis
|
Taylor & Francis
4 publications, 5%
|
American Chemical Society (ACS)
|
American Chemical Society (ACS)
3 publications, 3.75%
|
SAGE
|
SAGE
3 publications, 3.75%
|
Wolters Kluwer Health
|
Wolters Kluwer Health
2 publications, 2.5%
|
Wiley
|
Wiley
2 publications, 2.5%
|
Society for Neuroscience
|
Society for Neuroscience
1 publication, 1.25%
|
Mary Ann Liebert
|
Mary Ann Liebert
1 publication, 1.25%
|
Annual Reviews
|
Annual Reviews
1 publication, 1.25%
|
Oxford University Press
|
Oxford University Press
1 publication, 1.25%
|
5
10
15
20
25
|
- We do not take into account publications that without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.